

Gambia Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Gambia			
2. Grant number: 17-GMB-12c-X / 17-GMB-25a-Y /			
3. Date of Decision Letter: 16th of December 2016			
4. Date of the Partnership Framework Agreement: 3 February 2014			
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID, Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID ¹			
8. Programme duration²: 2009 -2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2009-2016	2017	Total ³
Programme Budget (US\$)	US\$7,977,915 ⁴	US\$1,086,000	US\$9,063,915

¹ Country requested a switch to PCV13, 4 dose vial, in 2017. The timing of the first shipments of PCV13, 4 dose vial, will be determined during the development of the 2017 shipment plan based on your desired timing, the stock of the existing presentation of PCV, supply availability, and programmatic readiness to switch. Wastage has been estimated at 10% to align with WHO indicative wastage for the PCV13 4 dose vial and co-financing is aligned with your desired presentation in anticipation of the switch.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>10. Vaccine introduction grant (in US\$): Country qualifies for a product switch grant of up to US\$ 30,000 to support the PCV switch. The funding will be transferred upon approval of the budget for utilisation of the product switch grant. Funding will be transferred through UNICEF.</p>																
<p>11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)⁵</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Gavi funds in each year</th> <th>2009-2016</th> <th>2017</th> </tr> </thead> <tbody> <tr> <td>Number of Pneumococcal vaccines doses</td> <td></td> <td>289,100</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>US\$7,977,915⁶</td> <td>US\$1,086,000</td> </tr> </tbody> </table>			Type of supplies to be purchased with Gavi funds in each year	2009-2016	2017	Number of Pneumococcal vaccines doses		289,100	Annual Amounts (US\$)	US\$7,977,915 ⁶	US\$1,086,000					
Type of supplies to be purchased with Gavi funds in each year	2009-2016	2017														
Number of Pneumococcal vaccines doses		289,100														
Annual Amounts (US\$)	US\$7,977,915 ⁶	US\$1,086,000														
<p>12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.</p>																
<p>13. Self-procurement: Not applicable</p>																
<p>14. Co-financing obligations: Reference code: 17-GMB-12c-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2017</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>17,800</td> </tr> <tr> <td>Number of AD syringes</td> <td></td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$58,594</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$61,500</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2017	Number of vaccine doses	17,800	Number of AD syringes		Number of re-constitution syringes		Number of safety boxes		Value of vaccine doses (US\$)	US\$58,594	Total co-financing payments (US\$) (including freight)	US\$61,500
Type of supplies to be purchased with Country funds in each year	2017															
Number of vaccine doses	17,800															
Number of AD syringes																
Number of re-constitution syringes																
Number of safety boxes																
Value of vaccine doses (US\$)	US\$58,594															
Total co-financing payments (US\$) (including freight)	US\$61,500															

⁵ This is the amount that Gavi has approved.

⁶ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

15. Operational support for campaigns: Not applicable		
	2017	2018
Grant amount (US\$)	US\$	
16. Additional reporting requirements: Not applicable		
Reports and other information	Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
17. Financial clarifications: Not applicable		
<i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>		
18. Other conditions: Not applicable		

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

16th of December 2016